Cargando…

Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study

BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smoke...

Descripción completa

Detalles Bibliográficos
Autores principales: Montes de Oca, Maria, Victorina Lopez Varela, Maria, Laucho-Contreras, Maria E., Casas, Alejandro, Schiavi, Eduardo, Mora, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401386/
https://www.ncbi.nlm.nih.gov/pubmed/28431499
http://dx.doi.org/10.1186/s12890-017-0414-6
_version_ 1783231037088727040
author Montes de Oca, Maria
Victorina Lopez Varela, Maria
Laucho-Contreras, Maria E.
Casas, Alejandro
Schiavi, Eduardo
Mora, Juan Carlos
author_facet Montes de Oca, Maria
Victorina Lopez Varela, Maria
Laucho-Contreras, Maria E.
Casas, Alejandro
Schiavi, Eduardo
Mora, Juan Carlos
author_sort Montes de Oca, Maria
collection PubMed
description BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smokers and/or exposed to biomass, attending routine primary care visits completed a questionnaire and performed spirometry. COPD was defined as post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) < 0.70; asthma was defined as either prior asthma diagnosis or wheezing in the last 12 months plus reversibility (increase in post-bronchodilator FEV(1) or FVC ≥200 mL and ≥12%); ACOS was defined using a combination of COPD with the two asthma definitions. Exacerbations in the past year among the subgroups were evaluated. RESULTS: One thousand seven hundred forty three individuals completed the questionnaire, 1540 performed acceptable spirometry, 309 had COPD, 231 had prior asthma diagnosis, and 78 asthma by wheezing + reversibility. ACOS prevalence in the total population (by post-bronchodilator FEV(1)/FVC < 0.70 plus asthma diagnosis) was 5.3 and 2.3% by post-bronchodilator FEV(1)/FVC < 0.70 plus wheezing + reversibility. In the obstructive population (asthma or COPD), prevalence rises to 17.9 and 9.9% by each definition, and to 26.5 and 11.3% in the COPD population. ACOS patients defined by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility had the lowest lung function measurements. Exacerbations for ACOS showed a prevalence ratio of 2.68 and 2.20 (crude and adjusted, p < 0.05, respectively) (reference COPD). CONCLUSIONS: ACOS prevalence in primary care varied according to definition used. ACOS by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility represents a clinical phenotype with more frequent exacerbations, which is probably associated with a different management approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-017-0414-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5401386
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54013862017-04-24 Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study Montes de Oca, Maria Victorina Lopez Varela, Maria Laucho-Contreras, Maria E. Casas, Alejandro Schiavi, Eduardo Mora, Juan Carlos BMC Pulm Med Research Article BACKGROUND: Asthma–COPD overlap syndrome (ACOS) prevalence varies depending on the studied population and definition criteria. The prevalence and clinical characteristics of ACOS in an at-risk COPD primary care population from Latin America was assessed. METHODS: Patients ≥40 years, current/ex-smokers and/or exposed to biomass, attending routine primary care visits completed a questionnaire and performed spirometry. COPD was defined as post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) < 0.70; asthma was defined as either prior asthma diagnosis or wheezing in the last 12 months plus reversibility (increase in post-bronchodilator FEV(1) or FVC ≥200 mL and ≥12%); ACOS was defined using a combination of COPD with the two asthma definitions. Exacerbations in the past year among the subgroups were evaluated. RESULTS: One thousand seven hundred forty three individuals completed the questionnaire, 1540 performed acceptable spirometry, 309 had COPD, 231 had prior asthma diagnosis, and 78 asthma by wheezing + reversibility. ACOS prevalence in the total population (by post-bronchodilator FEV(1)/FVC < 0.70 plus asthma diagnosis) was 5.3 and 2.3% by post-bronchodilator FEV(1)/FVC < 0.70 plus wheezing + reversibility. In the obstructive population (asthma or COPD), prevalence rises to 17.9 and 9.9% by each definition, and to 26.5 and 11.3% in the COPD population. ACOS patients defined by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility had the lowest lung function measurements. Exacerbations for ACOS showed a prevalence ratio of 2.68 and 2.20 (crude and adjusted, p < 0.05, respectively) (reference COPD). CONCLUSIONS: ACOS prevalence in primary care varied according to definition used. ACOS by post-bronchodilator FEV(1)/FVC < 0.7 plus wheezing + reversibility represents a clinical phenotype with more frequent exacerbations, which is probably associated with a different management approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-017-0414-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-21 /pmc/articles/PMC5401386/ /pubmed/28431499 http://dx.doi.org/10.1186/s12890-017-0414-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Montes de Oca, Maria
Victorina Lopez Varela, Maria
Laucho-Contreras, Maria E.
Casas, Alejandro
Schiavi, Eduardo
Mora, Juan Carlos
Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title_full Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title_fullStr Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title_full_unstemmed Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title_short Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
title_sort asthma–copd overlap syndrome (acos) in primary care of four latin america countries: the puma study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401386/
https://www.ncbi.nlm.nih.gov/pubmed/28431499
http://dx.doi.org/10.1186/s12890-017-0414-6
work_keys_str_mv AT montesdeocamaria asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy
AT victorinalopezvarelamaria asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy
AT lauchocontrerasmariae asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy
AT casasalejandro asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy
AT schiavieduardo asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy
AT morajuancarlos asthmacopdoverlapsyndromeacosinprimarycareoffourlatinamericacountriesthepumastudy